BMEA BIOMEA FUSION INC

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Additionally, Biomea’s management team will be hosting one-on-one meetings throughout the conference, taking place from January 13 to January 16.

A live audio webcast of the presentation can be accessed or by visiting the Investors & Media section of Biomea’s website at . A replay of the webcast will be available following the live presentation.

About Biomea Fusion 

Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.  

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure.  

Visit us at biomeafusion.com and follow us on , and . 

Contact:  

Ramses Erdtmann  

COO & President of Biomea Fusion 

  



EN
06/01/2025

Underlying

BMEABIOMEA FUSION INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMEA FUSION INC

 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rul...

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, in e...

April 1, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Resu...

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDW...

March 31, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Announces Leadership Transition

Biomea Fusion Announces Leadership Transition Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) --  Biomea Fusion, Inc. (“Biomea,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Th...

March 25, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabete...

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p

March 24, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rul...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’...

March 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch